New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:46 EDTNBSNeoStem begins research collaboration for Scleroderma skin wound treatment
NeoStem announced that it has signed an agreement for a research collaboration investigating the potential of very small embryonic-like stem cells, or VSELs, in treating difficult to heal wounds in an animal model of scleroderma. The collaboration is funded in part by a previously announced $147,765 grant from the Small Business Innovative Research Program for the "Development of Adult Pluripotent Very Small Embryonic Like Stem Cells to Treat Skin Wounds in Scleroderma" from the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, or NIH-NIAMS. The study will employ the tight skin mouse to test the potential wound healing capabilities of autologous VSELs in treating difficult to heal skin ulcers characteristic of this disease. Depending on the results of the study, the company may qualify for up to an additional $1.5M phase 2 grant for the indication from NIH-NIAMS.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
16:09 EDTNBSNeoStem provides 2015 outlook
In 2015, NeoStem's management expects significant additional achievements. The Company's milestones and goals for the year include: Randomization of the first patient for the Intus Phase 3 trial for NBS20 in the second quarter of 2015; Release of one-year data from PreSERVE AMI Phase 2 trial for NBS10 on March 15, 2015 at the Annual Scientific Sessions of the American College of Cardiology; Finalization of decision on next development steps for NBS10 based on PreSERVE primary analysis results in the second half of 2015; Initiation of a Phase 2 study for which NeoStem has received FDA agreement on the protocol to evaluate in adolescents the use of NBS03D, a Treg-based therapeutic being developed to treat type 1 diabetes, in late 2015 or 2016 depending on resource availability; Further exploration of means by which the Company can take advantage of new regulations in Japan that permit conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy; Continued growth of the Company's client services business; Advancement of initiatives to lower costs and improve efficiency of manufacturing in anticipation of production for NeoStem's own products and those of its clients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use